Ipsen: Accelerating profitable growth in pharma
Part One: Ipsen, a global pharmaceutical firm headquartered in France, was facing significant challenges, including regulatory setbacks and fierce competition, when David Loew assumed the role of CEO in 2020. The loss of exclusivity for Somatuline, Ipsen’s flagship cancer drug, added to the complexities. Tasked by the board, Loew aimed to lead Ipsen into a new era of profitable growth amid escalating competition. After thorough review during the Covid-19 pandemic, Loew and the executive team recognized the critical importance of the upcoming strategy. Ipsen Investors’ Day became the platform to unveil “Focus. Together. For Patients and Society,” the strategy shaping Ipsen’s trajectory toward ambitious 2025 targets. Despite pandemic disruptions, Loew was confident that Ipsen possessed the essential elements to embark on a new path of profitable growth. Part Two: Three years after launching the new strategy, David Loew concluded a meeting with the head of legal affairs, reflecting on the strategy’s journey. Structured around four pillars, the strategy prioritized patient-centricity, a sustainable pipeline, improved efficiency and operational excellence through collaboration and a diverse workforce. Ipsen’s ambition was to be an adaptable force, creating lasting value. While Ipsen made significant strides in executing the strategy, recognizing market acknowledgment, critical questions persisted. These revolved around geographic footprint, digital integration, ongoing cultural transformation and the accelerated development of key products alongside acquisitions to fortify the pipeline. Loew prepared for a two-day session with the executive team to capitalize on successes and chart the way forward to future-proof the company.
- Understand Ipsen’s strategic transformation: Gain insights into its transformation journey, from its historical roots to its current strategic direction under David Loew’s leadership.
- Understand Ipsen’s competitive environment and the macro factors that have shaped the pharma industry and will influence its future evolution.
- Explore the need for a mid-sized global pharma to design a new strategy in view of likely future disruptions to the sector.
- Explore strategy design in a highly competitive industry.
- Think holistically about how to approach the design of a multi-year corporate strategy.
Ipsen, Healthcare, Biopharmaceuticals, Healthcare, Pharmaceuticals
2019-2024
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
Bossard, a Swiss company founded in 1731, has successfully transitioned from a product-centric approach to one that offers services and solutions. It has achieved significant revenue growth despite economic challenges. Its brand promise, “proven p...
99designs.com is a global platform connecting freelance designers with potential clients. The case study examines the potential impact of generative AI on 99designs’ business model. The platform uses a crowdsourcing approach that invites designers...
In this study, we analyze how the performance-aspiration gap influences strategic change in family firms, providing evidence of the moderating role of family ownership in this relationship. According to socioemotional wealth (SEW) theory, family o...
The call by the former Italian prime minister and ECB president for massive investment in the EU is a wake-up call to Europe's economic stagnation. But can the continent afford the trade-offs it is overlooking?
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
in Review of Managerial Science October 2024, vol. 18, pp. 2981-3005 https://doi.org/10.1007/s11846-023-00703-3
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications